In-hospital outcomes with thrombolytic therapy in patients with renal dysfunction presenting with acute ischaemic stroke

Nephrology Dialysis Transplantation

Volumn 25, Issue 4, 2010, Pages 1150-1157

  Agrawal, Varun ^a   Rai, Baroon ^b   Fellows, Jonathan ^c   McCullough, Peter A ^c  

^a BAYSTATE MEDICAL CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Chronic kidney disease; Intracerebral haemorrhage; Modified Rankin score; Mortality; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANGIOTENSIN RECEPTOR ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

AGED; ARTICLE; ASYMPTOMATIC HEMORRHAGE; BLOOD PRESSURE; BRAIN HEMORRHAGE; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FIBRINOLYTIC THERAPY; FUNCTIONAL ASSESSMENT; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PETECHIA; PRIORITY JOURNAL; RANKIN SCALE; SAMPLE SIZE; SIDE EFFECT; SUBARACHNOID HEMORRHAGE; SYMPTOMATIC HEMORRHAGE;

AGED; FEMALE; FIBRINOLYTIC AGENTS; GLOMERULAR FILTRATION RATE; HUMANS; INTRACRANIAL THROMBOSIS; ISCHEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 77950273506     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp619     Document Type: Article

References (48)

1. Khella S, Bleicher MB. Stroke and its prevention in chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 1343-1351
2. Seliger SL, Gillen DL, Tirschwell D, et al. Risk factors for incident stroke among patients with end-stage renal disease. J Am Soc Nephrol 2003; 14: 2623-2631
3. Seliger SL, Gillen DL, Longstreth WT Jr, et al. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 2003; 64: 603-609
4. Nakayama M, Metoki H, Terawaki H, et al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population-the Ohasama study. Nephrol Dial Transplant 2007; 22: 1910-1915
5. Abramson JL, Jurkovitz CT, Vaccarino V, et al. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC study. Kidney Int 2003; 64: 610-615
6. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 2007; 115: 478-534
7. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study GroupTissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587
8. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian acute stroke study investigators. Lancet 1998; 352: 1245-1251
9. Albers GW, Clark WM, Madden KP, et al. Atlantis trial: results for patients treated within 3 hours of stroke onset. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. Stroke 2002; 33: 493-495
10. Kirtane AJ, Piazza G, Murphy SA, et al. Correlates of bleeding events among moderate-to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the protect-timi-30 trial. J Am Coll Cardiol 2006; 47: 2374-2379
11. Fox KA, Antman EM, Montalescot G, et al. The impact of renal dysfunction on outcomes in the EXTRACT-TIMI 25 trial. J Am Coll Cardiol 2007; 49: 2249-2255
12. Sica D. The implications of renal impairment among patients undergoing percutaneous coronary intervention. J Invasive Cardiol 2002; 14 Suppl B: 30B-37B
13. Washam JB, Adams GL. Risks and benefits of antiplatelet therapy in uremic patients. Adv Chronic Kidney Dis 2008; 15: 370-377
14. McCullough PA. Acute coronary syndromes in patients with renal failure. Curr Cardiol Rep 2003; 5: 266-270
15. Shoji T, Emoto M, Tabata T, et al. Advanced atherosclerosis in pre-dialysis patients with chronic renal failure. Kidney Int 2002; 61: 2187-2192
16. Anavekar NS, Pfeffer MA. Cardiovascular risk in chronic kidney disease. Kidney Int Suppl 2004: S11-S155
17. Ikram MA, Vernooij MW, Hofman A, et al. Kidney function is related to cerebral small vessel disease. Stroke 2008; 39: 55-61
18. Martinez-Vea A, Salvado E, Bardaji A, et al. Silent cerebral white matter lesions and their relationship with vascular risk factors in middle-aged predialysis patients with CKD. Am J Kidney Dis 2006; 47: 241-250
19. Wada M, Nagasawa H, Iseki C, et al. Cerebral small vessel disease and chronic kidney disease (CKD): results of a cross-sectional study in community-based Japanese elderly. J Neurol Sci 2008; 272: 36-42
20. Gibson CM, Pinto DS, Murphy SA, et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 2003; 42: 1535-1543
21. Baruah DB, Dash RN, Chaudhari MR, et al. Plasminogen activators: a comparison. Vascul Pharmacol 2006; 44: 1-9
22. Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke 2007; 38: 1091-1096
23. Bravata DM, Kim N, Concato J, et al. Thrombolysis for acute stroke in routine clinical practice. Arch Intern Med 2002; 162: 1994-2001
24. Yahalom G, Schwartz R, Schwammenthal Y, et al. Chronic kidney disease and clinical outcome in patients with acute stroke. Stroke 2009; 40: 1296-1303
25. Friedman PJ. Serum creatinine: an independent predictor of survival after stroke. J Intern Med 1991; 229: 175-179
26. MacWalter RS, Wong SY, Wong KY, et al. Does renal dysfunction predict mortality after acute stroke? A 7-year follow-up study. Stroke 2002; 33: 1630-1635
27. Mattana J, Effiong C, Gooneratne R, et al. Outcome of stroke in patients undergoing hemodialysis. Arch Intern Med 1998; 158: 537-541
28. Iseki K, Fukiyama K. Clinical demographics and long-term prognosis after strokein patientsonchronic haemodialysis. The Okinawa dialysis study (OKIDS) group. Nephrol Dial Transplant 2000; 15: 1808-1813
29. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047
30. Bos MJ, Koudstaal PJ, Hofman A, et al. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam study. Stroke 2007; 38: 3127-3132
31. Iseki K, Kinjo K, Kimura Y, et al. Evidence for high risk of cerebral hemorrhage in chronic dialysis patients. Kidney Int 1993; 44: 1086-1090
32. Kawamura M, Fijimoto S, Hisanaga S, et al. Incidence, outcome, and risk factors of cerebrovascular events in patients undergoing maintenance hemodialysis. Am J Kidney Dis 1998; 31: 991-996
33. Larrue V, von Kummer RR, Muller A, et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: A secondary analysis of the European-Australasian acute stroke study (ECASS II). Stroke 2001; 32: 438-441
34. Ingall TJ, O'Fallon WM, Asplund K, et al. Findings from the reanal-ysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 2004; 35: 2418-2424
35. Marti-Fabregas J, Bravo Y, Cocho D, et al. Frequency and predictors of symptomatic intracerebral hemorrhage in patients with ischemic stroke treated with recombinant tissue plasminogen activator outside clinical trials. Cerebrovasc Dis 2007; 23: 85-90
36. Montaner J, Rodriguez-Yanez M, Castellanos M, et al. Molecular signatures of course and prognosis of intracerebral hemorrhage. Seminars in Cerebrovascular Diseases and Stroke 2006; 5: 178-188
37. Felberg RA, Okon NJ, El-Mitwalli A, et al. Early dramatic recovery during intravenous tissue plasminogen activator infusion: clinical pattern and outcome in acute middle cerebral artery stroke. Stroke 2002; 33: 1301-1307
38. Demchuk AM, Tanne D, Hill MD, et al. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology 2001; 57: 474-480
39. Hrafnkelsdottir T, Ottosson P, Gudnason T, et al. Impaired endothe-lial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertension. Hypertension 2004; 44: 300-304
40. Saposnik G, Young B, Silver B, et al. Lack of improvement in patients with acute stroke after treatment with thrombolytic therapy: predictors and association with outcome. JAMA 2004; 292: 1839-1844
41. Ringleb PA, Schwark C, Kohrmann M, et al. Thrombolytic therapy for acute ischaemic stroke in octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome. J Neurol Neurosurg Psychiatry 2007; 78: 690-693
42. Berrouschot J, Rother J, Glahn J, et al. Outcome and severe hemor-rhagic complications of intravenous thrombolysis with tissue plas-minogen activator in very old (> or = 80 years) stroke patients. Stroke 2005; 36: 2421-2425
43. Tanne D, Gorman MJ, Bates VE, et al. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: the tPA stroke survey experience. Stroke 2000; 31: 370-375
44. Gomez-Choco M, Obach V, Urra X, et al. The response to IV rt-PA in very old stroke patients. Eur J Neurol 2008; 15: 253-256
45. Heuschmann PU, Kolominsky-Rabas PL, Roether J, et al. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA 2004; 292: 1831-1838
46. Bateman BT, Schumacher HC, Boden-Albala B, et al. Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002. Stroke 2006; 37: 440-446
47. McCullough PA. Treatment disparities in patients with acute coronary syndromes and kidney disease. Eur Heart J 2009; 30: 526-527
48. Hacke W, Kaste M, Bluhmki E, et al. ECASS Investigators. Throm-bolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008 Sep 25; 359: 1317-1329